⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798377 | 0.91 | ITGB1 (0.31) | — | |
| SCHEMBL21798136 | 0.91 | — | — | |
| SCHEMBL21798071 | 0.90 | — | — | |
| SCHEMBL21798194 | 0.80 | — | — | |
| SCHEMBL25588884 | 0.79 | EPHX2 (0.31) | — | |
| SCHEMBL21798054 | 0.79 | APLNR (0.37) | — | |
| SCHEMBL23145807 | 0.76 | — | — | |
| SCHEMBL23145417 | 0.71 | — | — | |
| SCHEMBL15706017 | 0.69 | — | — | |
| SCHEMBL25348203 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250353820-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-12338220-B2 | Antiviral pyrazolopiridinone compounds | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4479388-A1 | ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024049803-A1 | BICYCLIC HETEROCYCLE COMPOUNDS FOR TREATMENT OF HERPES VIRUSES | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| EP-4034537-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | Novartis AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114667285-A | Antiviral pyrazolopyridinone compounds | 诺华股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| EP-3849979-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | Novartis AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112996789-A | Antiviral pyridopyrazinedione compounds | 诺华股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC | 2021-05-06 | — | — | US | disclosed |
| WO-2021061898-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| WO-2020053654-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-12 | — | — | US | disclosed |